AbbVie Inc. with price, financials, news flow, and insider context in one page.
AbbVie Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where ABBV sits inside Healthcare and Drug Manufacturers - General, and the key financial markers that matter before moving into a fuller research workflow.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
This page is structured for research context, not a trade call. It gives you a clean read on where ABBV sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 15B | 695M | 3.56B |
| Q4 2025 | 16.62B | 1.82B | 4.89B |
| Q3 2025 | 15.78B | 186M | 6.64B |
| Q2 2025 | 15.42B | 938M | 4.88B |
This is Goldman's second downward revision in a week, which gives the cuts additional weight as a directional signal rather than a knee-jerk reaction. The bring-forward of Persian Gulf export norma...
On Monday, the Dow Jones Industrial Average climbed to new intraday and closing records on a potential deal between the U.S. and Iran.
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
AbbVie Inc. (ABBV) — questions investors ask
What is the current stock price of AbbVie Inc. (ABBV)?
AbbVie Inc. (ABBV) is trading at $221.59, down 2.70% in the latest session. The live price and one-year chart on this page update through the trading day.
What is AbbVie Inc.'s market capitalization?
AbbVie Inc. has a market capitalization of about 391.5B, derived from the latest share price and shares outstanding.
When is AbbVie Inc.'s next earnings date?
AbbVie Inc. is next expected to report earnings on Jul 30, 2026. The ABBV earnings page tracks the estimate and reporting history.
What is AbbVie Inc.'s P/E ratio?
AbbVie Inc. trades at a forward price-to-earnings ratio of 13.63 — one measure of how the market is pricing its future earnings.
What is ABBV's 52-week trading range?
Over the past 52 weeks, ABBV has traded between $181.73 and $244.81.
What sector is AbbVie Inc. in?
AbbVie Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry.
Does AbbVie Inc. pay a dividend?
AbbVie Inc. currently carries a dividend yield of about 100.0%.
What is the analyst price target for ABBV?
The mean analyst price target for ABBV is $253.55, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This ABBV page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.